Carcinogenesis, Vol. 23, No. 10, 1751-1758,
October 2002
© 2002 Oxford University Press
CARCINOGENESIS |
Mutations induced by 
-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats
1 Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA,
2 Centro de Química Estrutural, Complexo I, Instituto Superior Técnico, Av. Rovisco Pais, 1049-001 Lisboa, Portugal,
3 Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA
The antiestrogen tamoxifen is widely used for the treatment of breast cancer and more recently for the prevention of breast cancer. A concern over the use of tamoxifen as a chemopreventive agent is its carcinogenicity in rat liver, through a genotoxic mechanism involving 
-hydroxylation, esterification, and DNA adduct formation, primarily by reaction with dG. In a recent study [Gamboa da Costa et al., Cancer Lett., 176, 37–45 (2002)], we demonstrated a significant increase in the mutant frequency in the lacI gene of Big Blue rats treated with tamoxifen, and a further increase in rats administered -hydroxytamoxifen. In the present study, we have assessed mutation induction by tamoxifen and -hydroxytamoxifen in the liver cII gene of Big Blue rats and have characterized the types of mutations induced by -hydroxytamoxifen in the liver lacI and cII genes. The mutant frequencies in the liver cII gene were 80 ± 13 x 10–6 in the control, 112 ± 13 x 10–6 in the tamoxifen-treated group (P < 0.01 vs. control), and 942 ± 114 x 10–6 in the -hydroxytamoxifen-treated animals (P < 0.001 vs. control; P < 0.001 vs. tamoxifen). Molecular analysis of the mutants indicated that the -hydroxytamoxifen-induced mutational spectrum differed significantly from the control spectrum, but was very similar to the spectrum induced by tamoxifen for both the lacI and cII genes [Davies et al., Environ. Mol. Mutagen., 28, 430–433 (1996); Davies et al., Carcinogenesis, 20, 1351–1356 (1999)]. G:C 
T:A transversion was the major type of mutation induced by -hydroxytamoxifen and tamoxifen, while G:C A:T transition was the main type of mutation in the control. These results support the hypothesis that -hydroxytamoxifen is a major proximate tamoxifen metabolite causing the initiation of tumors in the liver of rats treated with tamoxifen.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Liapis, K. I.E. McLuckie, P. D. Lewis, P. B. Farmer, and K. Brown Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots Nucleic Acids Res., September 19, 2008; (2008) gkn586v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, X. Liu, R. H. Heflich, and T. Chen Time Course of cII Gene Mutant Manifestation in the Liver, Spleen, and Bone Marrow of N-Ethyl-N-Nitrosourea-Treated Big Blue Transgenic Mice Toxicol. Sci., November 1, 2004; 82(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Slikker III, N. Mei, and T. Chen N-Ethyl-N-nitrosourea (ENU) Increased Brain Mutations in Prenatal and Neonatal Mice but Not in the Adults Toxicol. Sci., September 1, 2004; 81(1): 112 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|